OP95
Anti-BRCA2 (Ab-1) Mouse mAb (2B)
liquid, clone 2B, Calbiochem®
Synonim(y):
Anti-Breast Cancer Susceptibility Protein
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Kod UNSPSC:
12352203
NACRES:
NA.43
Polecane produkty
pochodzenie biologiczne
mouse
Poziom jakości
forma przeciwciała
purified antibody
rodzaj przeciwciała
primary antibodies
klon
2B, monoclonal
Postać
liquid
zawiera
≤0.1% sodium azide as preservative
reaktywność gatunkowa
human
producent / nazwa handlowa
Calbiochem®
warunki przechowywania
OK to freeze
izotyp
IgG2b
Warunki transportu
wet ice
temp. przechowywania
−20°C
docelowa modyfikacja potranslacyjna
unmodified
informacje o genach
human ... BRCA2(675)
Opis ogólny
Anti-BRCA2 (Ab-1), mouse monoclonal, clone 2B, recognzies the ~460 kDa BRCA2 protein in cells expressing a wild type BRCA2 gene. It is validated for Western blotting and immunoprecipitation.
Purified mouse monoclonal antibody generated by immunizing mice with the specified immunogen and fusing splenocytes with myeloma cells. Recognizes the ~460 kDa BRCA2 protein.
Recognzies the ~460 kDa BRCA2 protein in cells expressing a wild type BRCA2 gene. Sold under license of U.S. Patent 5,753,441 and 6,162,897.
Immunogen
Human
a recombinant protein consisting of amino acids 1651-1821 of human BRCA2 fused to GST
Zastosowanie
Immunoblotting (2 µg/ml)
Immunoprecipitation (2 µg)
Immunoprecipitation (2 µg)
Opakowanie
Please refer to vial label for lot-specific concentration.
Ostrzeżenie
Toxicity: Standard Handling (A)
Postać fizyczna
In PBS.
Rekonstytucja
Following initial thaw, aliquot and freeze (-20°C).
Komentarz do analizy
Positive Control
MCF7 cells
MCF7 cells
Inne uwagi
Andres, J.L., et al. 1998. Oncogene16, 2229.
Chen, J., et al. 1998. Mol. Cell2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA95, 5287.
Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA95, 13869.
Connor, F., et al. 1997. Nat. Genet.17, 423.
Sharan, S.K., et al. 1997. Nature386, 804.
Ludwig, T., et al. 1997. Genes Dev.11, 1226.
Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA94, 6927.
Rajan, J.V., et al. 1997. Dev. Biol.184, 385.
Suzuki, A., et al. 1997. Genes Dev.11, 1242.
Wong, A.K.C., et al. 1997. J. Biol. Chem.272, 31941.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol.23, 1.
Goggins, M., et al. 1996. Cancer Res.56, 5360.
Stratton, M.R. 1996. Hum. Mol. Genet.5, 1515.
Tavtigian, S.V., et al. 1996. Nat. Genet.12, 333.
Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA93, 13078.
Spillman, M.A. and A.M. Bowcock. 1996. Oncogene13, 1639.
Vaughn, J.P., et al. 1996. Cancer Res.56, 4590.
Wooster, R., et al. 1995. Nature378, 789.
Chen, J., et al. 1998. Mol. Cell2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA95, 5287.
Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA95, 13869.
Connor, F., et al. 1997. Nat. Genet.17, 423.
Sharan, S.K., et al. 1997. Nature386, 804.
Ludwig, T., et al. 1997. Genes Dev.11, 1226.
Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA94, 6927.
Rajan, J.V., et al. 1997. Dev. Biol.184, 385.
Suzuki, A., et al. 1997. Genes Dev.11, 1242.
Wong, A.K.C., et al. 1997. J. Biol. Chem.272, 31941.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol.23, 1.
Goggins, M., et al. 1996. Cancer Res.56, 5360.
Stratton, M.R. 1996. Hum. Mol. Genet.5, 1515.
Tavtigian, S.V., et al. 1996. Nat. Genet.12, 333.
Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA93, 13078.
Spillman, M.A. and A.M. Bowcock. 1996. Oncogene13, 1639.
Vaughn, J.P., et al. 1996. Cancer Res.56, 4590.
Wooster, R., et al. 1995. Nature378, 789.
The CAPAN-1 cell line, which has 6174delT mutation in the single BRCA2 allele, expresses a truncated BRCA2 protein of 230 kDa that contains the Anti-BRCA2 epitope and retains RAD51 binding but has lost p53 binding. Full length BRCA2 protein will co-migrate on SDS-PAGE with the catalytic subunit of DNA PK which can be detected using Anti-DNA PK, Cat. No. PC127. Antibody should be titrated for optimal results in individual systems.
Informacje prawne
Sold under license of U.S. Patents 5,837,492 and 6,124,104.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
This page may contain text that has been machine translated.
Nie możesz znaleźć właściwego produktu?
Wypróbuj nasz Narzędzie selektora produktów.
Kod klasy składowania
11 - Combustible Solids
Klasa zagrożenia wodnego (WGK)
WGK 1
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
M Goggins et al.
Cancer research, 56(23), 5360-5364 (1996-12-01)
Germline mutations in BRCA2 predispose carriers to the development of breast, ovarian, and a variety of other cancers. The original localization of the BRCA2 gene was aided by its homozygous deletion in a pancreatic carcinoma; indeed, an excess of pancreatic
A K Wong et al.
The Journal of biological chemistry, 272(51), 31941-31944 (1998-01-24)
Recent work has shown that the murine BRCA2 tumor suppressor protein interacts with the murine RAD51 protein. This interaction suggests that BRCA2 participates in DNA repair. Residues 3196-3232 of the murine BRCA2 protein were shown to be involved in this
F Connor et al.
Nature genetics, 17(4), 423-430 (1997-12-17)
Germline mutation of the BRCA2 gene carries a high risk of developing breast cancer. To study the function of this gene, we generated a mutation in Brca2 in mice. Unlike other mutations in the Brca2 gene, which are lethal early
J V Rajan et al.
Developmental biology, 184(2), 385-401 (1997-04-15)
Germline mutations in the putative tumor suppressor gene, BRCA1, predispose women to dramatically elevated risks of breast cancer, while germline mutations in the structurally unrelated gene, BRCA2, predispose both men and women to breast cancer. Recent studies have suggested an
S V Tavtigian et al.
Nature genetics, 12(3), 333-337 (1996-03-01)
Breast carcinoma is the most common malignancy among women in developed countries. Because family history remains the strongest single predictor of breast cancer risk, attention has focused on the role of highly penetrant, dominantly inherited genes in cancer-prone kindreds (1).
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej